PMID- 34115896
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 47
IP  - 1
DP  - 2022 Jan
TI  - Evaluation of efficacy and safety of oral voriconazole in the management of 
      recalcitrant and recurrent dermatophytosis.
PG  - 30-36
LID - 10.1111/ced.14799 [doi]
AB  - BACKGROUND: Dermatophytosis is a worldwide public health problem, affecting > 25% 
      of the world's population. There has been a rampant increase in the resistant, 
      recurrent dermatophytosis in the past few years, especially in India. Azole 
      resistance in dermatophytes has been reported to be as high as 19% worldwide, 
      hence evaluating the efficacy and safety of a newer oral antifungal is important. 
      AIM: To evaluate the efficacy and safety of oral voriconazole in the management 
      of recalcitrant and recurrent dermatophytosis. METHODS: Patients with extensive, 
      recurring and resistant dermatophytosis. The clinical diagnosis was confirmed by 
      potassium hydroxide staining. Patients were given a 2-week course of oral 
      voriconazole, administered as 800 mg on Day 1, followed by two daily doses of 
      200 mg (total 400 mg/day) for the remaining 13 days. The patients were followed 
      up in Week 2 to assess response and in Week 6 to assess recurrence. Patients were 
      monitored for any adverse effects (AEs). RESULTS: In total, 40 patients completed 
      the study. Complete clearance was seen in 90% and 75% at Weeks 2 and 6, 
      respectively. By the end of Week 6, eight patients (20%) had partial improvement 
      of disease without complete clearance and only 5% had recurrence. No AEs were 
      recorded during the treatment course. CONCLUSION: Voriconazole, a novel oral 
      antifungal that can be used for treatment of recurrent and resistant 
      dermatophytosis, has a good efficacy and safety profile with a very low rate of 
      recurrence.
CI  - (c) 2021 British Association of Dermatologists.
FAU - B S, Chandrashekar
AU  - B S C
AD  - Department of Dermatology, Cutis Academy of Cutaneous Science, Bangalore, 
      Karnataka, India.
FAU - D S, Poojitha
AU  - D S P
AD  - Department of Dermatology, Cutis Academy of Cutaneous Science, Bangalore, 
      Karnataka, India.
LA  - eng
PT  - Journal Article
DEP - 20210817
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Antifungal Agents)
RN  - JFU09I87TR (Voriconazole)
SB  - IM
CIN - Clin Exp Dermatol. 2021 Dec;46(8):1621-1623. PMID: 34189762
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antifungal Agents/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Tinea/*drug therapy
MH  - Treatment Outcome
MH  - Voriconazole/*administration & dosage/adverse effects
MH  - Young Adult
EDAT- 2021/06/12 06:00
MHDA- 2022/03/04 06:00
CRDT- 2021/06/11 17:27
PHST- 2021/05/13 00:00 [revised]
PHST- 2020/09/22 00:00 [received]
PHST- 2021/06/10 00:00 [accepted]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/06/11 17:27 [entrez]
AID - 10.1111/ced.14799 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2022 Jan;47(1):30-36. doi: 10.1111/ced.14799. Epub 2021 Aug 
      17.